Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Ch...
27 Setembro 2019 - 9:00AM
Business Wire
Following its regularly scheduled meeting, the Board of
Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive
Chairman of the Board Ian C. Read has chosen to retire on December
31, 2019, and that it has unanimously elected Pfizer’s Chief
Executive Officer (CEO), Dr. Albert Bourla, to succeed him as
Chairman of the Board of Directors effective January 1, 2020.
Bourla will also retain the CEO role.
Ian Read joined Pfizer in 1978. He was named CEO of Pfizer in
2010, and Chairman of the Board of Directors in 2011.
“It’s been my greatest privilege to serve alongside Pfizer
colleagues for the past 41 years. Their compassion, integrity,
intellectual rigor and commitment to patients are what make Pfizer
such an extraordinary company, and I’m proud to have been part of
its history,” stated Ian Read. “I have tremendous confidence in
Albert, the board and our colleagues, and believe that Pfizer’s
best days are yet to come – which is an exciting thought for
patients and their families across the globe.”
Albert Bourla stated, “I am honored to have been chosen to
succeed Ian as the Chairman of the Board of this wonderful company.
It truly is an opportunity of a lifetime to be appointed Chairman
at such a dynamic time for Pfizer, the pharmaceutical industry, and
the patients around the world who rely on our medicines and
vaccines. Driven by our purpose – breakthroughs that change
patients’ lives – we can have a meaningful impact on more people
than ever was imagined.
“I want to thank Ian for his unwavering dedication to Pfizer
over the past four decades and during this leadership transition.
As a result of his unrelenting focus on culture, creating value and
developing talent, Pfizer has become a stronger and more stable
institution. His leadership and counsel have been invaluable to the
company, and more personally, I have benefited greatly from Ian’s
advice, guidance and friendship,” continued Bourla.
Shantanu Narayen, Lead Independent Director of Pfizer’s Board of
Directors, stated,” On behalf of the Board of Directors, I want to
congratulate Ian for his distinguished career and thank him for his
steadfast service to Pfizer. Ian has been a model of corporate
leadership and integrity in the industry and beyond. We wish him
well in his retirement.”
“The naming of Albert as Chairman is the result of a systemic
and comprehensive succession plan undertaken by the board several
years ago. Albert brings a unique set of skills that the board has
observed firsthand during his tenure as CEO, and while serving as
Chief Operating Officer and the leader of several global
businesses. All of this makes him the logical choice to take on the
role of Chairman at this important point in Pfizer’s history. We
are confident that Albert, with his unwavering passion for
patients, will do an excellent job leading our board, while
continuing to advise management and shepherd the business,”
continued Narayen.
Pfizer Inc.: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Disclosure Notice
The information contained in this release is as of September 27,
2019. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new
information or future events or developments.
This release contains forward-looking information about, among
other things, Pfizer’s anticipated future prospects that involves
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such
statements. Risks and uncertainties include, among other things,
the uncertainties inherent in research and development; the
uncertainties inherent in business and financial planning,
including, without limitation, risks related to Pfizer’s business
and prospects, adverse developments in Pfizer’s markets, or adverse
developments in the U.S. or global capital markets, credit markets,
regulatory environment or economies generally; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2018 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results,” as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190927005072/en/
Investor Relations:
Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com
Media Relations:
Patricia Kelly
+1 (212) 733-3810
Patricia.Kelly@Pfizer.com
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024